Method of treating diabetes mellitus using KGF
First Claim
Patent Images
1. A method of treating diabetes mellitus, comprising administering to a mammal having that condition an amount effective for reducing blood glucose levels compared to an untreated individual of a keratinocyte growth factor having amino acid residues 32-194 of SEQ ID NO:
- 2 (native KGF) or an analog thereof which comprises a difference from the sequence of native KGF by having an amino acid deletion of or having a residue other than cysteine substituted for Cys32 and Cys46 of SEQ ID-NO;
2, wherein said keratinocyte growth factor exhibits at least 500-fold greater stimulation of BALB/MK keratinocyte cells than that of NIH/3T3 fibroblast cells and at least about 500-fold greater stimulation of BALB/MK keratinocyte cells than for BS/589 epithelial cells or for CC1208 epithelial cells, as determined by H-thymidine incorporation.
2 Assignments
0 Petitions
Accused Products
Abstract
A method and pharmaceutical compositions are described for the use of keratinocyte growth factor to treat diabetes mellitus in mammals.
48 Citations
11 Claims
-
1. A method of treating diabetes mellitus, comprising administering to a mammal having that condition an amount effective for reducing blood glucose levels compared to an untreated individual of a keratinocyte growth factor having amino acid residues 32-194 of SEQ ID NO:
- 2 (native KGF) or an analog thereof which comprises a difference from the sequence of native KGF by having an amino acid deletion of or having a residue other than cysteine substituted for Cys32 and Cys46 of SEQ ID-NO;
2, wherein said keratinocyte growth factor exhibits at least 500-fold greater stimulation of BALB/MK keratinocyte cells than that of NIH/3T3 fibroblast cells and at least about 500-fold greater stimulation of BALB/MK keratinocyte cells than for BS/589 epithelial cells or for CC1208 epithelial cells, as determined by H-thymidine incorporation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- 2 (native KGF) or an analog thereof which comprises a difference from the sequence of native KGF by having an amino acid deletion of or having a residue other than cysteine substituted for Cys32 and Cys46 of SEQ ID-NO;
Specification